ZTA Biotech, a Budapest, Hungary-based biotech startup, has developed a covid-19 antibody (IgG) test using the enzyme-linked immunosorbent assay (ELISA) protocol. This new detection method represents an advance in determining if patients have had covid-19 and if they might still have immunity to the disease. Independently validated early results have proven 100% in specificity after testing 280 samples and 100% sensitivity by testing 260 samples of recovered and symptomatic patients.
The ELISA protocol is designed for use postvaccination. Its microplates are coated with critical antigens which are the prime targets of the current vaccine developments. The kit can also be used to monitor past natural exposure to SARS-CoV-2 and to evaluate the possibility of re- infection.
With a potential market of 5.8 billion people, who will likely need multiple antibody tests in the coming years, the formula has a massive potential across the globe. ZTA Biotech is currently offering the intellectual property rights to licensees and/or to a sole-rights purchaser in order to help bring the formula to market.
For more information, visit ZTA Biotech.
